Merck & Co., Inc. (MRK)
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.
Is Merck Stock A Trap At $110?
Merck stock surged more than 10% in a month after management delivered a confidence shock on January 12th. They're now projecting that their next-generation drugs—treatments for cardiometabolic, respiratory, and infectious diseases—will yield $70 billion by the mid-2030s.
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Revolution is developing drugs that target a molecular driver of cancers.
Merck in Talks to Buy Revolution Medicines Per Financial Times Report
Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.
Merck (MRK) Surpasses Market Returns: Some Facts Worth Knowing
Merck (MRK) concluded the recent trading session at $110.99, signifying a +2.2% move from its prior day's close.
Why Merck (MRK) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck: Fundamentals Amplified By A Momentum Breakout
Merck has surged nearly 30% since my prior bullish call, reflecting strong share price momentum. MRK fundamentals are robust, underpinned by stellar financial performance and promising regulatory developments. Valuation remains highly attractive, with improving market sentiment supporting continued upside.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
